Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elan Corporation

http://www.elan.com

Latest From Elan Corporation

Organon: Humira A ‘Whole Different Animal’ To Other US Biosimilars

Shortly after filing for a high-concentration biosimilar adalimumab product with partner Samsung Bioepis, Organon has provided in-depth commentary for its expectations around the impending formation of the market, forecasting a “free for all” six months post-formation.

Biosimilars Pricing Strategies

Samsung Bioepis Aims To Compete On Higher-Strength Humira In US

Samsung Bioepis and Organon have revealed plans to compete with higher-concentration formulations of adalimumab in the US, after the FDA accepted for review an sBLA for a citrate-free 100mg/ml version of the SB5 Hadlima biosimilar that is already approved in a 50mg/ml formulation.

Biosimilars Strategy

Merck KGaA's M Ventures Moving On Up With €600m Boost

The new capital will allow the VC arm to create and finance "a new and larger portfolio of innovative companies that align with the future strategies" of Merck's businesses.

Financing Business Strategies

Krystal Sees Success With Topical Gene Therapy In Debilitating Rare Skin Disorder

A regulatory filing for Vyjuvek in the US is targeted for the first half of 2022 following the positive results of a Phase III trial, positioning Krystal for its first commercial launch.

Gene Therapy Dermatology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Onclave Therapeutics Limited
UsernamePublicRestriction

Register